Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

BioNano Genomics Is Proving Value Is What You Are Willing To Pay

By MarketBeat.com (Chris Markoch )Stock MarketsMar 25, 2021 06:43AM ET
www.investing.com/analysis/bionano-genomics-is-proving-value-is-what-you-are-willing-to-pay-200569418
BioNano Genomics Is Proving Value Is What You Are Willing To Pay
By MarketBeat.com (Chris Markoch )   |  Mar 25, 2021 06:43AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

After soaring in the pre-market upon the release of its earnings report, shares of BioNano Genomics (NASDAQ:BNGO)are down 3% in mid-day trading. Although there was a lot to like in the company’s report, investors may still be trying to rationalize if BNGO stock is priced too high.

Since Dec. 22, 2020, BNGO stock has soared 1,378%. But the question is why? The company last reported earnings in November and the stock didn’t move. Yet a month later it starts a massive rally. Institutional investors have begun to show more interest in the stock. Institutional ownership (as of this writing) is at about 5.3% which is significantly higher than the prior quarter.

And the company just received a target price upgrade from Oppenheimer to $15 per share. However, overall, analysts have a consensus price target that suggests BNGO stock will go down, not up in the short term.

Perhaps more troubling for retail investors is that volume is down significantly. That could change of course, but a larger question right now is should more investors take an interest in BNGO stock at its current price?

The Future of Genomics

There is no question that BioNano is doing important work. The company’s leadership in the field of genomic structure analysis is unquestioned. Structural analysis picks up where gene sequencing leaves off.

The basic idea is that information is power. In this case, structural analysis provides information that is not detectable by gene sequencing. This gives doctors a greater likelihood of rationalizing a patient’s symptoms. This in turn can lead to a more targeted approach to therapeutic treatments. In the future, structural analysis could lead to the widespread application of gene editing procedures.

How the Saphyr System is Different?

Structural analysis has been around for years, but BioNano has what amounts to a better mousetrap. Allow me to briefly explain. When it first became a thing, genomic structure analysis was a series of distinct processes. The problem with these separate processes are time and cost. To run each of these processes separately took time and had a hefty price tag. And it also required specialized expertise.

The Saphyr system takes an all-in-one approach that combines these processes into a single diagnostics system. The Saphyr system addresses the problems of time and cost. The system allows structural analysis to be performed much faster and they have driven down the cost to perform its gene analysis to around $450 per gene.

In the company’s earnings report, BioNano said it was able to increase its installed base of Saphyr systems from 24 at the end of 2019 to 97 at the end of last year. This indicates that its addressable market is seeing value in the system.

Growth Through Acquisition

BioNano posted $4 million in fourth quarter revenue, a 43% increase in year-over-year revenue. And a good bit of that revenue ($1.1 million) came from its acquisition of Lineagen. This company provides diagnostic services that are sought after by BioNano’s customer base. And, it’s a key step in ensuring that the cost of its services will be reimbursed by health insurance providers.

Too Far, Too Fast?

The central concern that I have is that the bullish case for BioNano existed well before last December. But back then, BNGO stock was literally a penny stock. And there simply doesn’t seem to be enough new news to justify the parabolic leap in BNGO stock.

But this is where we are. Retail investors are doing the heavy lifting here. And they believe that BioNano Genomics has a value that justifies the price, even if the payoff for that value may be years down the road.

BioNano operates in a sector that has the potential to be a disruptive force. However, for now I think the good news to the tune of nearly $1.5 billion in equity value is priced into BNGO stock.

Original Post

BioNano Genomics Is Proving Value Is What You Are Willing To Pay
 

Related Articles

BioNano Genomics Is Proving Value Is What You Are Willing To Pay

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email